The AIMTM technology presents a broad range of product development opportunities.
Current R&D efforts are focused on the development of artificial cellular matrix platforms and testing of the platforms for properties that are compatible for use as human therapeutics. This pre-clinical R&D work should lead to the initiation of at least two clinical development programs within the next 2 years.
NexImmune is focused on the development of cancer immuno -therapies.
There are several other product opportunities, for example development of an aAPC for the prevention and treatment of acute CMV viral infection following bone marrow transplant.
Further advancement of the technology through proof-of-principle studies in cancer, transplant, and other diseases.